Monday, December 16, 2019

tgiHealthCareerp

  • Personal Health
  • Health News
  • Medications
  • Health Problems
  • Kids Health
  • Family Health
  • Beauty & Balance

Home ยป Phase

Medications 

Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH

04/18/2019 2, Albireo, Announces, Clearance, Commence, Elobixibat, FDA, for, IND, NAFLD/NASH, of, Phase, The, to, Treatment, Trial

BOSTON, April 11, 2019 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing

Read more
Medications 

Pfizer Initiates Phase 2b/3 Clinical Trial for PF-06651600, an Oral JAK3 Inhibitor, for the Treatment of Patients with Moderate to Severe Alopecia Areata

01/05/2019 2b/3, Alopecia, an, Areata, Clinical, for, Inhibitor, Initiates, JAK3, Moderate, of, Oral, Patients, PF-06651600, Pfizer, Phase, Severe, The, to, Treatment, Trial, with

January 3, 2019 — Pfizer Inc. (NYSE: PFE) announced today the initiation of a Phase 2b/3 clinical trial for its

Read more
Medications
New weapon in war against opioids: An implanted device that automatically releases lifesaving naloxone

Side effects mild, brief with single antidepressant dose of intravenous ketamine

Of all professions, construction workers most likely to use opioids and cocaine

Health News
High blood pressure: Best supplement to lower your reading

Christmas Tree Syndrome Might Be The Real Reason For Your December 'Flu'

Lung cancer symptoms: The sign in your breath that could signal the deadly disease

Health Problems
Recruitment of miR-8080 by luteolin inhibits AR-V7 in castration-resistant prostate cancer

Trends in Alzheimer’s disease diagnoses across the United States

Researchers study how altered protein degradation contributes to the development of tumors

Copyright © 2019 tgiHealthCareerp. All rights reserved.
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok